Spero therapeutics announces positive topline results from phase 1 bronchoalveolar lavage clinical trial of spr206, a novel intravenous next generation polymyxin antibiotic for the treatment of multi-drug resistant gram-negative infections in the hospital setting

Spr206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg

SPRO Ratings Summary

SPRO Quant Ranking